There are currently 56 active clinical trials seeking participants for Advanced Cancer research studies. The states with the highest number of trials for Advanced Cancer participants are Texas, California, Florida and New York.
Adagrasib in Combination With Nab-Sirolimus in Patients With Advanced Solid Tumors and Non-Small Cell Lung Cancer With a KRAS G12C Mutation (KRYSTAL -19)
NCT05840510
Recruiting
This study will evaluate the safety, MTD and/or RP2D, PK, and clinical activity of the combination of adagrasib with nab-sirolimus in patients with advanced solid tumors/NSCLC with a KRAS G12C mutation.
Gender:
All
Ages:
18 years and above
Trial Updated:
02/02/2024
Locations: Research Site, Cleveland, Ohio +2 locations
Conditions: Solid Tumor, Adult, NSCLC, Advanced Cancer, Metastatic Cancer, Malignant Neoplastic Disease
Register for Updates
A Study of MGC026 in Participants With Advanced Solid Tumors
NCT06242470
Recruiting
The study is designed to understand the safety, tolerability, pharmacokinetics, immunogenicity, and preliminary antitumor activity of MGC026 in participants with relapsed or refractory, unresectable, locally advanced or metastatic solid tumors The study has a dose escalation portion and a cohort expansion portion of the study. Participants will receive MGC026 by intravenous (IV) infusion. The dose of MGC026 will be assigned at the time of enrollment. Participants may receive up to 35 treatments... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
05/09/2024
Locations: START Midwest, Grand Rapids, Michigan +2 locations
Conditions: Advanced Solid Tumor, Advanced Cancer, Metastatic Cancer, Squamous Cell Carcinoma of Head and Neck, Non Small Cell Lung Cancer, Small-cell Lung Cancer, Bladder Cancer, Sarcoma, Endometrial Cancer, Melanoma, Castration Resistant Prostatic Cancer, Cervical Cancer, Colorectal Cancer, Gastric Cancer, Gastro-esophageal Cancer, Pancreas Cancer, Clear Cell Renal Cell Carcinoma, Hepatocellular Carcinoma, Platinum-resistant Ovarian Cancer
Register for Updates
Study of Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors (MK-3475-158/KEYNOTE-158)
NCT02628067
Recruiting
In this study, participants with multiple types of advanced (unresectable and/or metastatic) solid tumors who have progressed on standard of care therapy will be treated with pembrolizumab (MK-3475).
Gender:
All
Ages:
18 years and above
Trial Updated:
05/09/2024
Locations: Call for Information (Investigational Site 0008), New Brunswick, New Jersey +22 locations
Conditions: Advanced Cancer, Anal Carcinoma, Anal Cancer, Biliary Cancer, Cholangiocarcinoma, Bile Duct Cancer, Neuroendocrine Tumor, Carcinoid Tumor, Endometrial Carcinoma, Endometrial Cancer, Cervical Carcinoma, Cervical Cancer, Vulvar Carcinoma, Vulvar Cancer, Small Cell Lung Carcinoma, Small Cell Lung Cancer (SCLC), Mesothelioma, Thyroid Carcinoma, Thyroid Cancer, Salivary Gland Carcinoma, Salivary Gland Cancer, Salivary Cancer, Parotid Gland Cancer, Advanced Solid Tumors, Colorectal Carcinoma
Register for Updates
APL-101 Study of Subjects With NSCLC With c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors
NCT03175224
Recruiting
To assess: efficacy of APL-101 as monotherapy for the treatment of NSCLC harboring MET Exon 14 skipping mutations, NSCLC harboring MET amplification, solid tumors harboring MET amplification, solid tumors harboring MET fusion, primary CNS tumors harboring MET alterations, solid tumors harboring wild-type MET with overexpression of HGF and MET efficacy of APL-101 as an add-on therapy to EGFR inhibitor for the treatment of NSCLC harboring EGFR activating mutations and developed acquired resistanc... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
05/08/2024
Locations: Loma Linda University Medical Center, Loma Linda, California +90 locations
Conditions: Advanced Cancer, Renal Cancer, Gastric Cancer, Gastroesophageal Junction Adenocarcinoma, NSCLC, Lung Cancer, Brain Tumor, Glioblastoma Multiforme, Solid Tumors, EGFR Gene Mutation, MET Amplification, HGF, Thyroid Cancer, Pancreatic Cancer, Colon Cancer, MET Alteration, MET Fusion, Exon 14 Skipping
Register for Updates
Psychophysical Studies of Cancer Therapy Pain
NCT00515060
Recruiting
The Aim of this Study is to examine the feasibility of using quantitative sensory testing procedures, widely applied to the experimental study of sensory processing in humans both with and without various pain syndromes, to now characterize the psychophysical properties of neuropathic pain that has developed as a consequence of cancer therapy. Skin punch biopsies will be performed in patients with chemotherapy-induced pain to determine whether the impairment of nerve function is due to actual re... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
05/07/2024
Locations: University of Texas MD Anderson Cancer Center, Houston, Texas
Conditions: Advanced Cancer, Pain
Register for Updates
Trial of Two Adagrasib Dosing Regimens in NSCLC With KRAS G12C Mutation (KRYSTAL 21)
NCT05853575
Recruiting
This study will evaluate the efficacy of two dosing regimens of adagrasib (600 mg BID versus 400 mg BID) in patients with NSCLC with KRAS G12C mutation.
Gender:
All
Ages:
18 years and above
Trial Updated:
05/06/2024
Locations: Providence Medical Foundation, Santa Rosa, California +16 locations
Conditions: Advanced Cancer, Metastatic Cancer, Malignant Neoplasm of Lung
Register for Updates
Study of AB598 Monotherapy and Combination Therapy in Participants With Advanced Cancers
NCT05891171
Recruiting
The primary purpose of this study is to assess the safety and tolerability of AB598 when taken alone, and in combination with zimberelimab and standard chemotherapy in participants with advanced malignancies.
Gender:
All
Ages:
18 years and above
Trial Updated:
05/01/2024
Locations: Lake City Cancer Care, LLC., Lake City, Florida +9 locations
Conditions: Advanced Cancer, Advanced Malignancies, Bladder Cancer, Cervical Cancer, Esophageal Cancer, Gastric Cancer, Gastroesophageal-junction Cancer (GEJ), Head and Neck Squamous Cell Carcinoma (HNSCC), Non-Small Cell Lung Cancer (NSCLC), Ovarian Cancer, Renal Cell Carcinoma (RCC), Triple Negative Breast Cancer (TNBC)
Register for Updates
A Study of AB801 Monotherapy and Combination Therapy in Participants With Advanced Malignancies
NCT06120075
Recruiting
The primary purpose of this study is to assess the safety and tolerability of AB801 in participants with advanced malignancies, and to determine a recommended AB801 dose for expansion.
Gender:
All
Ages:
18 years and above
Trial Updated:
05/01/2024
Locations: START MIdwest, Grand Rapids, Michigan +5 locations
Conditions: Advanced Cancer
Register for Updates
A Study to Provide Continued Access to and Assess Long-Term Safety of the Study Drug(s)
NCT06174987
Recruiting
This open-label, multicenter, rollover study will provide continued treatment for participants deriving benefit from different therapies received in studies sponsored by Daiichi Sankyo, Inc. (DS) or DS/Astra Zeneca (AZ)-sponsored study (eg. DS8201-A-J101, DS8201-A-U201, DS8201-A-U204, DS8201-A-U207, DS8201-A-U303).
Gender:
All
Ages:
18 years and above
Trial Updated:
05/01/2024
Locations: Miami Cancer Institute, Miami, Florida +23 locations
Conditions: Advanced Cancer, Metastatic Cancer
Register for Updates
Psilocybin Therapy in Advanced Cancer
NCT05398484
Recruiting
The purpose of this research is to study the safety and effects of single-dose psilocybin 25mg versus an active placebo (single dose niacin 100mg) in the treatment of anxiety, depression, and existential distress (i.e., loss of meaning and hope; fear of death) in advanced cancer (i.e., stage 3 or 4). Study medications will be administered in conjunction with brief psychotherapy that is designed to treat anxiety, depression and existential distress in advanced cancer.
Gender:
All
Ages:
Between 21 years and 100 years
Trial Updated:
04/30/2024
Locations: University of Colorado Anschutz Medical campus (CU AMC), Aurora, Colorado +1 locations
Conditions: Advanced Cancer
Register for Updates
A Study of SNS-101 (Anti VISTA) Monotherapy and in Combination With Cemiplimab in Patients With Advanced Solid Tumors
NCT05864144
Recruiting
Phase 1/2 study to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and efficacy of SNS-101, a novel anti VISTA IgG1 monoclonal antibody as monotherapy or in combination with cemiplimab in patients with advanced solid tumors.
Gender:
All
Ages:
18 years and above
Trial Updated:
04/30/2024
Locations: Sanford Cancer Center, Sioux Falls, South Dakota +3 locations
Conditions: Solid Tumor, Adult, Advanced Solid Tumor, Head and Neck Cancer, Breast Cancer, Colon Cancer, Pancreatic Cancer, Gastric Cancer, Esophageal Cancer, Prostate Cancer, Uterine Cancer, Cervix Cancer, Ovarian Cancer, Kidney Cancer, Bladder Cancer, Thyroid Cancer, Melanoma, Sarcoma, Advanced Cancer, Metastatic Cancer, Refractory Cancer, Non Small Cell Lung Cancer
Register for Updates
Evaluation of RBS2418 in Subjects With Advanced, Metastatic Solid Tumors
NCT05270213
Recruiting
RBS2418 (investigational product) is a specific immune modulator, working through ectonucleotide pyrophosphatase/phosphodiesterase I (ENPP1), designed to lead to anti-tumor immunity by increasing endogenous 2'-3'-cyclic guanosine monophosphate-adenosine monophosphate (cGAMP) and adenosine triphosphate (ATP levels) and reducing adenosine production in the tumors. RBS2418 has the potential to be an important therapeutic option for subjects both as monotherapy and in combination with checkpoint blo... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
04/29/2024
Locations: Honor Health Research Institute, Scottsdale, Arizona +11 locations
Conditions: Advanced Cancer
Register for Updates